APA (7th ed.) Citation

S, S., MS, D., E, O., C, M., D, B., E, G., . . . M, H. (2023). Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya. Wellcome open research, 8, 450. https://doi.org/10.12688/wellcomeopenres.19795.1

Chicago Style (17th ed.) Citation

S, Sang, et al. "Safety and Immunogenicity of Varied Doses of R21/Matrix-M™ Vaccine at Three Years Follow-up: A Phase 1b Age De-escalation, Dose-escalation Trial in Adults, Children, and Infants in Kilifi-Kenya." Wellcome Open Research 8 (2023): 450. https://doi.org/10.12688/wellcomeopenres.19795.1.

MLA (9th ed.) Citation

S, Sang, et al. "Safety and Immunogenicity of Varied Doses of R21/Matrix-M™ Vaccine at Three Years Follow-up: A Phase 1b Age De-escalation, Dose-escalation Trial in Adults, Children, and Infants in Kilifi-Kenya." Wellcome Open Research, vol. 8, 2023, p. 450, https://doi.org/10.12688/wellcomeopenres.19795.1.